Manoly Imthiaz, McAnelly Sarah-Louise, Sriskandarajah Sanjeevan, McLaughlin Kenneth Edward
Manchester Heart Centre, Central Manchester University Hospitals NHS Foundation Trust, Oxford Road, Manchester, UK
Manchester Heart Centre, Central Manchester University Hospitals NHS Foundation Trust, Oxford Road, Manchester, UK.
Interact Cardiovasc Thorac Surg. 2014 Aug;19(2):302-5. doi: 10.1093/icvts/ivu146. Epub 2014 May 8.
A best evidence topic in cardiac surgery was written according to a structured protocol. We addressed the following question: in patients who are diagnosed with carcinoid heart disease (CHD), do valvular surgeries improve their prognosis? Fifty percent of the patients with clinically diagnosed carcinoid syndrome had cardiac involvement which was present either as valvular dysfunction or as cardiac metastases. These patients often require surgery due to their heightened risk of cardiac disease. Altogether 217 relevant papers were identified as a result of the below-mentioned search, of which 10 papers represented the best evidence to answer the question. The author, journal, date and country of publication, patient group studied, study type, relevant outcomes, results and study weaknesses were tabulated. Of the patients who were identified to have carcinoid heart disease in different studies, 193 patients had valve procedure, mainly replacements at tricuspid, mitral and aortic valve positions and either valvuloplasty or replacement at pulmonary valve. Tricuspid and pulmonary valves represented the majority of the excised valves among patients undergoing valvular surgery for CHD. The pathology of carcinoid valve was attributed to the presence of plaque, causing thickening and retraction. Pure regurgitation was the most common finding in all the valves except pulmonary valve which had both stenosis and insufficiency. Thirty-day mortality was 17% (range 1-63%) and long-term survivors were reported to be alive at an average of 58 months (28-80 months) after the valve surgery. The evidence demonstrates that surgical intervention can lead to improved prognosis and reduce the symptoms of heart failure. Postoperative mortality was mainly due to the carcinoid disease itself and not as a complication of the surgery. Therefore, surgery could be considered for symptomatic palliation in carefully selected individuals.
一篇心脏外科的最佳证据主题文章是根据结构化协议撰写的。我们探讨了以下问题:在被诊断为类癌性心脏病(CHD)的患者中,瓣膜手术是否能改善其预后?临床诊断为类癌综合征的患者中有50%存在心脏受累,表现为瓣膜功能障碍或心脏转移。由于心脏病风险增加,这些患者通常需要手术。通过下述检索共识别出217篇相关论文,其中10篇论文代表了回答该问题的最佳证据。将作者、期刊、出版日期和国家、研究的患者组、研究类型、相关结局、结果及研究不足制成表格。在不同研究中被确定患有类癌性心脏病的患者中,193例患者接受了瓣膜手术,主要是在三尖瓣、二尖瓣和主动脉瓣位置进行置换,以及在肺动脉瓣进行瓣膜成形术或置换。在接受CHD瓣膜手术的患者中,三尖瓣和肺动脉瓣是切除瓣膜的主要类型。类癌瓣膜的病理表现为有斑块,导致增厚和回缩。除肺动脉瓣既有狭窄又有反流外,纯反流是所有瓣膜中最常见的表现。30天死亡率为17%(范围1 - 63%),据报道长期存活者在瓣膜手术后平均存活58个月(28 - 80个月)。证据表明手术干预可改善预后并减轻心力衰竭症状。术后死亡率主要归因于类癌疾病本身,而非手术并发症。因此,对于经过精心挑选的有症状患者可考虑手术以缓解症状。